Africa Molecular Point of Care Testing (using NAAT) Market, By Product (Instruments and Consumables & Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing, and Others), End User (Laboratories, Hospitals, Clinics, Ambulatory Centers, Homecare, Assisted Living Facilities, and Others), Mode of Testing (Prescription-Based Testing and OTC Testing), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2028.
Africa Molecular Point of Care Testing (using NAAT) Market Analysis and Insights
Africa molecular point of care testing (using NAAT) market is expected to grow due to improving healthcare facilities and infrastructures and the adoption of point-of-care testing at the hospital, laboratories, and clinics, which can drive the development of the market. The other factors anticipated to propel the growth of the molecular point of care testing (using NAAT) market include the rising prevalence of infectious diseases.
The other factors, such as the lack of skilled professionals and the high cost of customized molecular point of care testing (using NAAT), hamper the growth of the Africa molecular point of care testing (using NAAT) market. On the other hand, the increased healthcare expenditure and emerging countries with developed hospitals act as an opportunity to grow the Africa molecular point of care testing (using NAAT) market.
Data Bridge Market Research analyzes that the Africa molecular point of care testing (using NAAT) market will grow at a CAGR of 5.8% from 2021 to 2028.
|
Report Metric |
Details |
|
Forecast Period |
2021 to 2028 |
|
Base Year |
2020 |
|
Historic Years |
2019 |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Product (Instruments and Consumables & Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing, and Others), End User (Laboratories, Hospitals, Clinics, Ambulatory Centers, Homecare, Assisted Living Facilities, and Others), Mode of Testing (Prescription-Based Testing and OTC Testing), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) |
|
Countries Covered |
South Africa, Kenya, Nigeria and Rest of Africa |
|
Market Players Covered |
Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, Sysmex Corporation, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., PerkinElmer Inc. |
Market Definition of Africa Molecular Point of Care Testing (using NAAT) Market
POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting various disorders such as HIV, HPV, and respiratory disease through NAAT technology. NAAT is Nucleic Acid Amplification Techniques that allow the identification of pathogenic organisms by detecting their DNA or RNA.
In the worldwide pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propelled the growth of the market.
Africa Molecular Point of Care Testing (using NAAT) Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- INCREASE PREVALENCE OF CHRONIC DISEASES
It is a common fact that health degeneration starts with an increase in age. As the rate of chronic disease grows with time, the factors associated with the disease rates also increase. The high number of obese/ overweight population also has increased the prevalence of chronic diseases in various regions across the globe. The rise in the number of chronic diseases similar to HPV, STI, and TB, among more, has led to people opting for NAAT-based point-of-care and products for testing. Therefore, this might drive the growth of the Africa molecular point of care testing (using NAAT) market in the coming years.
- IMPROVEMENT IN DIAGNOSIS-SEEKING RATE
With the increase in the successful diagnosis of chronic diseases, including cancer, anemia, type 2 diabetes, and others, the improved health care professionals provide regular training sessions for the professionals for conducting tests in account for the improvement of diagnosis rate in the region. With the increase in the burden of diseases, the diagnosis rate is also increasing. With the advancements in the diagnosis, the rate is also growing for people going through the diagnosis.
- RISE IN PREFERENCE FOR HOMECARE TESTING
Home healthcare preferences make clinical information available at the right place and time. It will also help in reducing error and increasing safety with ensured quality. They also help elders in the case of a medical emergency. Many strategic changes have been made in health care to address point-of-care testing benefits. As per the World Health Organization (WHO), the number of people aged 65 and above is expected to rise from an estimated 524 million in 2010 to approximately 1.5 billion in 2050, with developed countries accounting for the majority of the increase.
Opportunities
- STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
An increase in the burden of chronic and non-chronic disease globally coupled with the rise in the geriatric population in Africa and Asia has created more demand for the development of new kits and solutions for molecular point-of-care testing with better efficacy and less time consumption. To provide diagnosis and screening in this region, the players in the market undergo partnership and agreement with each other to provide quality care through kits and instruments to the African population.
- RisE Healthcare Expenditure
Increasing healthcare expenditure and infrastructure can help patients take hassle-free advanced treatment to receive better diagnoses, procedures, and treatment for fast recovery. Point-of-care testing devices are beneficial for detecting various diseases and supporting treatment plans using POC software and solutions. Healthcare spending comprises out-of-pocket payments (people paying for their care), government expenditure, and sources including health insurance and activities by non-governmental organizations.
Restraints/Challenges
- HIGH COST OF PRODUCTS
The point-of-care testing products require a substantial considerable cost for the development process. As the concept needs to be locked down, the materials must be sourced, and it is essential to consider lead times. Additionally, the process is time-consuming as the device design needs sufficient time to fully mature before bringing to the market for use.
- LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
When compared with the results of laboratory testing standards, the NAAT testing results differ. Laboratory testing is more advanced, follows the process, protocol, and science for laboratory testing, and fully integrates with the technology necessary to analyze, validate, and document effects accurately. However, POCT/NAAT is undoubtedly associated with a lack of precise results. Molecular POCT cannot complete the standardization, and other critical criteria cannot achieve the standardization and different essential standards. It is a significant challenge for the Africa molecular point of care testing market. The PoC tests might sometimes provide erroneous results and suffers test results variability.
Post-COVID-19 Impact on Africa Molecular Point of Care Testing (using NAAT) Market
COVID-19 significantly impacted the molecular point of care testing (using NAAT) market. COVID-19 has positively affected the price and demand of molecular point of care testing (using NAAT) products at a higher level because of progressive online sales and technological advancements. The COVID-19 pandemic outbreak positively impacted the market's growth owing to the increased requirement for molecular point of care testing (using NAAT), especially in various hospitals. The current priority in most hospitals is given to COVID-19 treatments as the surge of COVID-19 cases is still persistent, which also increases the usage of molecular point of care testing (using NAAT). Moreover, many international governments and healthcare organizations have supported the supply of these products due to their high priority in crucial cases.
Recent Developments
- In November 2021, F.Hoffmann-La Roche Ltd announced that Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year. This increased the business doing capacity and business expansion in the forecast period
- In October 2021, Thermo Fisher Scientific Corporation received FDA approval for the TaqMan COVId-19 test SARS-COV molecular Assay. This increased the product portfolio of the company and contributed to the company revenue in the forecast period
Africa Molecular Point of Care Testing (using NAAT) Market Scope
Africa molecular point of care testing (using NAAT) market is categorized into five notable segments based on the product, indication, end user, mode of testing, and distribution channel. The growth amongst these segments will help to analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Instruments
- Consumables and Reagents
Based on product, the Africa molecular point of care testing (using NAAT) market is segmented into instruments and consumables and reagents.
Indication
- Sexually Transmitted Infection (STI) Testing
- Respiratory Infection Testing
- Gastrointestinal Tract Infection Testing
- Others
Based on indication, the Africa molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others.
End User
- Laboratories
- Hospitals
- Clinics
- Ambulatory Centers
- Home Care
- Assisted Living Facilities
- Others
Based on End User, the Africa molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others.
Mode of Testing
- Prescription-Based Testing
- OTC Testing
Based on mode of testing, the Africa molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Based on the distribution channel, the Africa molecular point of care testing (using NAAT) market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Africa Molecular Point of Care Testing (using NAAT) Market Regional Analysis/Insights
Africa molecular point of care testing (using NAAT) market is analyzed, and market size insights and trends are provided based on product, indication, end user, mode of testing, and distribution channel.
Africa molecular point of care testing (using NAAT) market report covers South Africa, Kenya, Nigeria and the rest of Africa.
South Africa dominates the Africa molecular point of care testing (using NAAT) market with a CAGR of around 6.1% in terms of market share and market revenue. It will continue to flourish its dominance during the forecast period. This is due to the rising prevalence of infectious and chronic diseases and the increasing technological advancements in the healthcare sector.
Competitive Landscape and Africa Molecular Point of Care Testing (using NAAT) Market Share Analysis
Africa molecular point of care testing (using NAAT) market competitive landscape provides details about the competitor. Components included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Africa presence, production sites and facilities, company strengths and weaknesses, product launch, regulatory guidelines, brand analysis, product approvals, product payload, application dominance, technology lifeline curve. The above data points are only related to the companies focus on the Africa molecular point of care testing (using NAAT) market.
Some major players operating in the Africa molecular point of care testing (using NAAT) market are Abbott, SD Biosensor, Thermo Fisher Scientific Inc., INC., bioMérieux SA, Danaher, Hologic, Inc., Seegene Inc., Sysmex Corporation, F. Hoffmann-La Roche Ltd, and others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES
4.3.1 CEPHEID
4.3.2 THERMO FISHER SCIENTIFIC INC.
4.3.3 HOLOGIC, INC.
4.3.4 BD
4.3.5 F. HOFFMANN-LA ROCHE LTD
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY
4.5 PRICE PER POCT INSTRUMENT
4.5.1 NORTH AMERICA
4.5.2 EUROPE
4.5.3 SOUTH ASIA
4.5.4 SOUTH EAST ASIA
4.5.5 MIDDLE EAST
4.5.6 AFRICA
4.6 PRICE PER TEST
4.6.1 NORTH AMERICA
4.6.2 EUROPE
4.6.3 SOUTH ASIA
4.6.4 SOUTH EAST ASIA
4.6.5 MIDDLE EAST
4.6.6 AFRICA
4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS
4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI)
4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS
4.1 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS
4.11 DISTRIBUTORS
4.11.1 NORTH AMERICA
4.11.2 EUROPE
4.11.3 SOUTH ASIA
4.11.4 SOUTH EAST ASIA
4.11.5 MIDDLE EAST
4.11.6 AFRICA
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 PANDEMIC OUTBREAK OF COVID-19
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 LACK OF ACCESSIBILITY
7 IMPACT OF COVID-19 ON THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19
7.5 CONCLUSION:
8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & REAGENTS
8.3 INSTRUMENTS
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)
9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS TESTING
9.2.1 COVID-19
9.2.2 FLU B
9.2.3 FLU A
9.2.4 RSV
9.2.5 TUBERCULOSIS
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)
9.2.7 OTHERS
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING
9.3.1 TV
9.3.2 CT
9.3.3 NG
9.3.4 HPV
9.3.5 HSV
9.3.6 MG
9.3.7 UU
9.3.8 MH
9.3.9 OTHERS
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING
9.4.1 GROUP B STREPTOCOCCUS
9.4.2 SHIGA TOXIN
9.4.3 H. PYLORI
9.5 OTHERS
10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER
10.1 OVERVIEW
10.2 LABORATORIES
10.3 HOSPITAL
10.4 CLINICS
10.5 AMBULATORY CENTER
10.6 HOMECARE
10.7 ASSISTED LIVING FACILITIES
10.8 OTHERS
11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING
11.1 OVERVIEW
11.2 PRESCRIPTION-BASED TESTING
11.3 OTC TESTING
12 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT SALES
12.3 THIRD PARTY DISTRIBUTOR
12.4 ONLINE SALES
13 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION
13.1 AFRICA
13.1.1 SOUTH AFRICA
13.1.2 KENYA
13.1.3 NIGERIA
13.1.4 REST OF AFRICA
14 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 DANAHER
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 HOLOGIC, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 F.HOFFMANN-LA-ROCHE LTD.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BINX HEALTH, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIOMERIEUX SA
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BIO-RAD LABORATORIES, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 CO-DIAGNOSTICS, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 GENMARK DIAGNOSTICS, INC
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GRIFOLS, S.A.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 LUCIRA HEALTH INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 MERIDIAN BIOSCIENCE
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 OXFORD NANOPORE TECHNOLOGIES
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 PERKIN ELMER INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 QIAGEN
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENTS
16.18 QUANTUMDX GROUP LTD.
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 QUIDEL CORPORATION
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 RANDOX LABORATORIES LTD.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 SD BIOSENSOR, INC.
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 SEEGENE INC,
16.22.1 COMPANY SNAPSHOT
16.22.2 REVENUE ANALYSIS
16.22.3 PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENT
16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENT
16.25 WONDFO
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)
TABLE 7 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 8 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 9 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 10 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 11 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 12 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 13 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 14 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 15 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 16 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 17 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 18 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 19 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 20 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 21 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 22 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 23 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 24 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 25 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 26 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 27 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 28 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 29 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 30 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 31 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 32 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 33 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 34 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 35 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 36 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 37 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 38 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 39 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 40 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 41 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 42 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 43 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 44 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 45 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 46 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 47 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 48 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 49 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 50 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 51 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 52 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 53 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 54 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 55 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 56 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 57 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 58 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 59 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 60 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 61 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 62 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 63 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 64 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 65 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 66 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 67 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 68 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 69 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 70 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 71 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 72 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 73 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 74 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 75 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 76 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 77 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 78 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 79 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 80 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 81 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 82 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 83 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 84 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 85 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 86 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 87 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 88 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 89 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 90 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 91 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 92 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 93 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 94 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 95 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 96 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 97 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 98 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 99 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 100 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 101 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 102 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 103 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 104 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 105 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 106 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 107 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 108 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 109 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 110 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 111 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 112 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 113 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 114 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 115 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 116 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 117 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 118 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 119 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 120 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 121 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 122 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 123 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 124 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 125 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 126 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 127 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 128 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 129 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 130 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 131 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 132 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 133 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 134 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 135 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 136 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 137 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 138 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 139 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 140 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 141 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 142 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 143 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 144 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 145 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 146 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 147 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 148 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 149 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 150 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 151 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 152 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 153 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 154 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 155 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 156 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 157 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 158 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 159 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 160 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 161 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 162 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 163 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 164 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 165 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 166 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 167 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 168 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 169 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 170 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 171 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 172 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 173 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 174 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 175 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 176 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 177 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 178 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 179 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 180 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 181 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 182 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 183 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 184 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 185 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 186 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 187 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 188 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 189 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 190 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 191 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 192 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 193 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 194 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 195 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 196 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 197 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 198 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 199 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 200 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 201 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 202 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 203 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 204 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 205 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 206 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 207 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 208 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 209 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 210 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 211 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 212 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 213 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 214 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 215 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 216 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 217 DISTRIBUTORS ACROSS NORTH AMERICA
TABLE 218 DISTRIBUTORS ACROSS EUROPE
TABLE 219 DISTRIBUTORS ACROSS SOUTH ASIA
TABLE 220 DISTRIBUTORS ACROSS SOUTH EAST ASIA
TABLE 221 DISTRIBUTORS ACROSS MIDDLE EAST
TABLE 222 DISTRIBUTORS ACROSS AFRICA
TABLE 223 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 224 AFRICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 225 AFRICA PEDIATRIC IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 226 AFRICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 228 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 229 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 230 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 231 AFRICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 232 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 233 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 234 AFRICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 235 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 236 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 237 AFRICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 238 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 239 AFRICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 240 AFRICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 241 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 242 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 243 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 244 AFRICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 245 AFRICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 246 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 247 AFRICA DIRECT SALES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 248 AFRICA THIRD PARTY DISTRIBUTOR IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 249 AFRICA ONLINE SALE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 250 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 251 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 252 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 253 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 254 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 255 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 256 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 257 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 258 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 259 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 260 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 261 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 262 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 263 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 264 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 265 SOUTH AFRICAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 266 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 267 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 268 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 269 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 270 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 271 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 272 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 273 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 274 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 275 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 276 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 277 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 278 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 279 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 280 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 281 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 282 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 283 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 284 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 285 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 286 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 287 REST OF AFRICA & AFRCIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 2 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION
FIGURE 3 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS
FIGURE 4 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID
FIGURE 11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
FIGURE 16 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016
FIGURE 17 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020
FIGURE 18 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 19 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 20 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020
FIGURE 22 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 23 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 24 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 25 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020
FIGURE 26 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 27 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 28 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020
FIGURE 30 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)
FIGURE 31 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)
FIGURE 32 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 33 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 34 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 35 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 36 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 38 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 39 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 41 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 42 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
